Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | AZD0901 + Capecitabine |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| AZD0901 | AZD-0901|AZD 0901|CMG901|CM-G901|CM G901 | CLDN18.2 Antibody 24 | AZD0901 is an antibody-drug conjugate (ADC) comprising an anti-CLDN18.2 antibody linked to the anti-microtubule agent monomethyl auristatin E (MMAE), which may induce antibody-dependent cellular cytotoxicity (ADCC) and inhibit tumor growth (PMID: 39232496). | |
| Capecitabine | Xeloda | R340|Ro 09-1978/000 | Chemotherapy - Antimetabolite 14 | Xeloda (capecitabine) is a prodrug that is converted to 5-FU, ultimately inhibiting RNA and DNA synthesis and cell division (PMID: 28520372). Xeloda (capecitabine) is FDA-approved for use in patients with colorectal, breast, gastric, esophageal, gastroesophageal junction, and pancreatic cancer (FDA.gov). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|